Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) – Research analysts at FBR & Co lifted their FY2016 EPS estimates for shares of Galmed Pharmaceuticals in a report released on Monday. FBR & Co analyst V. Bernardino now expects that the firm will post earnings of ($1.42) per share for the year, up from their prior forecast of ($1.52). FBR & Co has a “Buy” rating and a $20.00 price objective on the stock. FBR & Co also issued estimates for Galmed Pharmaceuticals’ Q4 2016 earnings at ($0.33) EPS, FY2017 earnings at ($0.97) EPS, FY2018 earnings at ($1.17) EPS, FY2019 earnings at $0.03 EPS and FY2020 earnings at ($0.62) EPS.

Galmed Pharmaceuticals (NASDAQ:GLMD) last released its quarterly earnings data on Monday, November 7th. The biopharmaceutical company reported ($0.34) EPS for the quarter, topping analysts’ consensus estimates of ($0.39) by $0.05.

Earnings History and Estimates for Galmed Pharmaceuticals (NASDAQ:GLMD)

GLMD has been the topic of a number of other research reports. HC Wainwright reiterated a “buy” rating on shares of Galmed Pharmaceuticals in a research note on Monday. Zacks Investment Research upgraded shares of Galmed Pharmaceuticals from a “hold” rating to a “buy” rating and set a $5.00 price objective on the stock in a research note on Wednesday, October 5th. Finally, Maxim Group reiterated a “buy” rating and set a $9.00 price objective (down previously from $24.00) on shares of Galmed Pharmaceuticals in a research note on Monday, August 1st. One analyst has rated the stock with a hold rating and four have given a buy rating to the company’s stock. Galmed Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $12.15.

Shares of Galmed Pharmaceuticals (NASDAQ:GLMD) opened at 3.49 on Wednesday. The stock’s 50 day moving average price is $4.03 and its 200-day moving average price is $4.35. Galmed Pharmaceuticals has a 12-month low of $2.78 and a 12-month high of $9.70. The firm’s market capitalization is $38.75 million.

A hedge fund recently bought a new stake in Galmed Pharmaceuticals stock. P.A.W. Capital Corp bought a new position in Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) during the third quarter, according to its most recent filing with the SEC. The institutional investor bought 60,000 shares of the biopharmaceutical company’s stock, valued at approximately $266,000. P.A.W. Capital Corp owned 0.54% of Galmed Pharmaceuticals as of its most recent filing with the SEC. 4.91% of the stock is currently owned by institutional investors.

About Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of once-daily, oral therapy for the treatment of liver diseases and cholesterol gallstones utilizing its synthetic fatty-acid/bile-acid conjugate (FABAC), called aramchol.

5 Day Chart for NASDAQ:GLMD

Receive News & Stock Ratings for Galmed Pharmaceuticals Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Galmed Pharmaceuticals Ltd. and related stocks with our FREE daily email newsletter.